Thyroid Scintigraphy: Tc-99m vs I-123 Imaging

Thyroid scintigraphy shows how the gland handles a radiotracer, and the choice between Tc-99m pertechnetate and I-123 iodide is a physics decision as much as a clinical one. Pertechnetate is trapped but not organified, images early, and gives a low thyroid dose; I-123 is trapped and organified, images later, and more faithfully reflects true iodine metabolism. Getting the tracer, timing, collimator, and dosimetry right is what makes a thyroid scan interpretable. ^{1, 9}

A thyroid "scan" is really a map of regional radiotracer uptake superimposed on an estimate of how much tracer the gland took up. Two radiopharmaceuticals dominate: sodium pertechnetate labeled with technetium-99m (Tc-99m), and sodium iodide labeled with iodine-123 (I-123). They are not interchangeable. Their photon energies drive collimator choice, their biochemistry drives imaging timing, and their retention drives dose. ^{1, 2}

This guide walks through the physics that separates the two tracers — decay characteristics, trapping versus organification, collimation, acquisition timing, quantitative uptake, and dosimetry — then covers the clinical decisions those physics enable, the practical acquisition tips that keep a scan diagnostic, and the regulatory context for handling byproduct material. DRPS supports thyroid imaging programs through its PET/CT and nuclear medicine physics and radiation safety officer services.

Introduction

The thyroid is a near-perfect nuclear medicine target because it concentrates iodine through a specific membrane transporter, the sodium-iodide symporter (NIS). Any tracer that the NIS recognizes will accumulate in functioning thyroid tissue, which is why both iodide and the iodide-mimic pertechnetate work. The gland's avidity for these tracers produces high target-to-background contrast and makes functional questions — is this nodule autonomous, is this tissue ectopic, is the gland hyperfunctioning diffusely or focally — answerable with a simple planar image. ^{1, 5}

But the two tracers diverge after the first step. Pertechnetate is trapped by the NIS and then released, because the gland cannot incorporate it into thyroid hormone. Iodide is trapped and then organified — bound into thyroglobulin — so it is retained. That single biochemical difference cascades into every practical choice: when you image, what the image means, and how much dose the patient receives. ^{1, 2}

Choosing well requires understanding both the nuclear physics of Tc-99m and I-123 and the physiology they probe. A physicist who sets up the camera, collimator, energy windows, and uptake-quantification method is as responsible for a defensible scan as the interpreting physician.

Topic Explanation

The two radionuclides

Technetium-99m decays by isomeric transition with a physical half-life of about 6.0 hours, emitting a 140.5 keV gamma ray in roughly 89% of decays. That energy is close to ideal for a modern gamma camera and a low-energy collimator, which is one reason Tc-99m underpins most of nuclear medicine. As pertechnetate (TcO₄⁻), it is an iodide analog: the NIS traps it, but the gland does not organify it. ^{1, 2}

Iodine-123 is cyclotron-produced and decays by electron capture with a physical half-life of about 13.2 hours, emitting a 159 keV gamma ray in roughly 83% of decays. As iodide, it behaves like stable iodine: trapped and organified, so it is retained and reflects genuine iodine handling. I-123 also emits a small fraction of higher-energy photons, and production can leave trace higher-mass iodine contaminants, both of which can contribute septal-penetration events that a careful collimator and energy-window choice must manage. ^{1, 2}

Trapping versus organification — the key distinction

This is the concept that makes or breaks interpretation:

• Pertechnetate (trapping only): accumulates during the trapping phase, then washes out because it cannot be organified. Imaging is performed early, about 15-30 minutes after injection, to catch the trapped signal before it clears. ¹
• Iodide (trapping + organification): accumulates and is retained in hormone synthesis. Imaging is performed later, commonly about 3-4 hours, and uptake quantification is classically reported at 24 hours. ¹

Most of the time the two agents agree. But a discordant nodule — hot on pertechnetate, cold on radioiodine — arises precisely because pertechnetate reports trapping while iodine reports trapping plus organification. Because a minority of discordant nodules are malignant, radioiodine imaging is the more specific test when nodule autonomy or cancer risk is the question. ^{1, 6}

For the quantitative counterpart of imaging — the radioiodine uptake measurement itself — see our companion guide to thyroid uptake measurement, and for the therapeutic use of iodine isotopes, see I-131 thyroid cancer therapy.

Key Technical Principles

Collimation and photon energy

Planar thyroid imaging is almost always done with a low-energy high-resolution (LEHR) parallel-hole collimator. For Tc-99m's 140 keV photon this collimator is well matched. For I-123's 159 keV photon it is still usable, but 159 keV sits near the upper end of a low-energy collimator's design range, and I-123's minor high-energy emissions can penetrate the collimator septa, adding a low-spatial-frequency haze that reduces contrast. Some programs therefore use a medium-energy collimator or a tailored energy window for I-123 to suppress septal penetration. ^{1, 7}

A pinhole collimator is frequently added for the thyroid because the gland is small and superficial. A pinhole magnifies the image and improves effective spatial resolution for detecting small nodules, lingual or ectopic tissue, and pyramidal lobes, at the cost of sensitivity and geometric distortion that the reader must account for. ⁷

Quantifying uptake

The functional value of a thyroid study is the percent uptake, which requires decay-corrected counting of a standard and the gland. The radioiodine uptake (RAIU) is computed as

where $C$ are count rates, $\lambda =\ln 2/T_{1/2}$ is the physical decay constant, and $t$ is the time between assaying the standard and counting the patient. The exponential term corrects the reference standard for physical decay so that gland and standard are compared on the same activity basis. A normal 24-hour RAIU with iodine is roughly 10-30%, though it depends on dietary iodine and the reference range of each laboratory. Pertechnetate trapping fractions are much lower, on the order of a few percent, because the tracer is not retained. ¹

Dosimetry: why the tracer choice changes dose

Because pertechnetate is not organified, it clears and delivers a comparatively low dose. The adult effective dose coefficient for Tc-99m pertechnetate is on the order of 0.013 mSv/MBq. A typical pertechnetate thyroid scan therefore produces a modest effective dose: ³

Iodine-123, being organified and retained, delivers more dose to the thyroid itself (the critical organ). Manufacturer dosimetry for sodium iodide I-123 gives an effective dose of about 2.2 mSv for the maximum diagnostic administration of 14.8 MBq, assuming 35% thyroid uptake — an effective dose coefficient near 0.15 mSv/MBq, though the thyroid equivalent dose is substantially higher and rises with uptake. ^{3, 4}

Both studies are firmly diagnostic-level exposures, but the difference explains why pertechnetate is attractive when minimizing thyroid dose matters and the clinical question only needs trapping information. Effective dose itself is a protection quantity defined by ICRP tissue-weighting factors, not a measure of individual risk. ⁸

Comparing the two tracers

The table is a decision aid, not a substitute for a facility protocol validated against the EANM/SNMMI guideline and the camera's own collimator and energy-window performance. ¹

Clinical Impact

The physics differences translate directly into what a scan can and cannot answer.

Diffuse versus focal hyperfunction. In hyperthyroidism, a uniformly increased uptake points to Graves disease, whereas one or more focal hot areas with suppression of the surrounding gland point to a toxic adenoma or toxic multinodular goiter. Either tracer can show the pattern, but when the next step is radioiodine therapy, an iodine-based study best predicts how the therapeutic isotope will distribute. ¹

Nodule autonomy and the discordant nodule. A hot nodule on pertechnetate suggests autonomy, but the specific question — will this nodule behave like functioning, iodine-avid tissue — is answered by radioiodine. The classic pitfall is the nodule that traps pertechnetate (hot) but fails to organify iodine (cold); such discordance has been reported with coexisting papillary carcinoma, which is why confirmatory radioiodine imaging is advised when malignancy is a concern. ⁶

Ectopic and residual tissue. Lingual thyroid, substernal extension, and residual or metastatic tissue are iodine-handling questions, favoring radioiodine. The avidity of functioning thyroid tissue for the NIS is also what makes rare findings — for example unexpected extrathyroidal uptake on a routine pertechnetate scan — occasionally reveal metastatic differentiated thyroid cancer. ^{1, 5}

Incidental uptake on other scans. Focal thyroid uptake seen incidentally on an FDG-PET performed for another indication can correspond to an autonomous nodule and warrants dedicated evaluation; the physics of why FDG and pertechnetate highlight different aspects of thyroid tissue is part of interpreting such incidental findings. ¹⁰

Practical Optimization Tips

1. Match the tracer to the question

Use pertechnetate for a fast, low-dose functional survey, in children, or when generator-based convenience matters. Use I-123 when organification, autonomy, ectopic tissue, or nodule confirmation is the clinical question. Document the rationale in the protocol. ¹

2. Choose and verify the collimator

Use an LEHR collimator for routine planar imaging and add a pinhole for magnified gland and nodule views. For I-123, evaluate whether septal penetration from minor high-energy photons is degrading contrast, and if so adjust the collimator or energy window. Confirm collimator performance as part of camera quality control. ^{1, 7}

3. Set energy windows deliberately

Center a symmetric photopeak window on 140 keV for Tc-99m and on 159 keV for I-123. For I-123, be aware that high-energy photons scattered or penetrating into the main window reduce contrast, and that asymmetric or additional windows are sometimes used to manage this. ¹

4. Standardize uptake quantification

Use a consistent neck phantom or standard, a fixed counting geometry, and correct the reference standard for physical decay with the exponential factor above. Small geometry inconsistencies are a leading cause of spurious uptake variation. ¹

5. Prepare the patient

Recent iodinated contrast, iodine-rich medications or supplements, and thyroid medications alter uptake and can render a study uninterpretable. Screen for these before scheduling, and manage pregnancy and lactation per guideline, since iodide crosses the placenta and concentrates in breast milk. ¹

Common pitfalls to avoid

• Treating pertechnetate and iodine as equivalent. They measure different steps; a hot pertechnetate nodule is not proof of iodine avidity. ⁶
• Imaging pertechnetate too late. It washes out; delayed imaging loses the trapped signal. ¹
• Ignoring septal penetration with I-123. Minor high-energy photons quietly degrade contrast if the collimator and window are not managed. ⁷
• Skipping decay correction of the uptake standard, which biases the reported percentage. ¹
• Missing an iodine-loading history, which is the most common reason an uptake study fails. ¹

Regulatory Considerations

Tc-99m and I-123 are byproduct (radioactive) material, so thyroid scintigraphy is governed by NRC 10 CFR Part 35 or an equivalent Agreement State program, not by the x-ray rules that cover CT or radiography. The medical-use framework sets authorized-user training, radiation safety officer responsibilities, dose calibrator quality control for assaying each administration, and record-keeping. Diagnostic administrations such as these do not require a written directive, which is reserved for therapy and for I-131 above regulatory thresholds, but the activity must still be measured and documented. ¹¹

Key frameworks to reference:

• 10 CFR Part 35 — Medical Use of Byproduct Material, governing authorized use, dose calibrator QC, and records. ¹¹
• ICRP Publication 128 — dose coefficients and biokinetic models for radiopharmaceuticals, including pertechnetate and iodide. ³
• ICRP Publication 103 — the tissue-weighting factors that define effective dose. ⁸
• EANM/SNMMI thyroid scintigraphy guideline — consensus recommendations for performing and interpreting thyroid scintigraphy and the radioiodine uptake test. ¹

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC for radioactive material. A facility must confirm which authority issues its license and which dose calibrator, survey, and record requirements apply. For the broader program context, see our guides to the radiation safety officer role and dose calibrator quality control.

Frequently Asked Questions (FAQs)

What is the difference between Tc-99m pertechnetate and I-123 for thyroid scanning?

Tc-99m pertechnetate is trapped by the sodium-iodide symporter but not organified, so it is imaged early (about 15-30 minutes) and reflects trapping only. I-123 iodide is both trapped and organified, is imaged at about 3-4 hours and sometimes 24 hours, and more faithfully reflects true iodine handling. Pertechnetate is cheaper, faster, and gives a lower thyroid dose; I-123 is preferred for evaluating nodule autonomy, ectopic tissue, and organification.

Why does the photon energy of the tracer matter for thyroid imaging?

Tc-99m emits a 140 keV gamma that is nearly ideal for a standard low-energy high-resolution collimator. I-123 emits a 159 keV gamma, which is still usable with a low-energy collimator but closer to its limit, and I-123 also produces minor high-energy photons that can penetrate collimator septa and degrade the image, which is why collimator choice and acquisition settings matter.

When is I-123 preferred over pertechnetate?

I-123 is preferred when true iodine handling is the question: evaluating autonomously functioning nodules, confirming or excluding a toxic adenoma, detecting ectopic or lingual thyroid tissue, assessing organification, and when a nodule that is hot on pertechnetate needs confirmation, because some pertechnetate-hot nodules are cold on iodine and can be malignant.

What collimator is used for thyroid scintigraphy?

A low-energy high-resolution parallel-hole collimator is standard for both Tc-99m pertechnetate and I-123. A pinhole collimator is frequently added for magnified, high-resolution views of the gland and nodules. For I-123, some programs use a collimator and energy-window strategy that limits the effect of minor high-energy photons.

How much radiation dose does a thyroid scan give?

Pertechnetate gives a relatively low dose because it is not retained; its adult effective dose coefficient is on the order of 0.013 mSv/MBq. I-123 iodide delivers more dose to the thyroid because it is organified and retained; a maximum diagnostic administration of about 14.8 MBq corresponds to an effective dose of roughly 2.2 mSv assuming 35% uptake. Both are diagnostic-level exposures.

What is a discordant thyroid nodule?

A discordant nodule appears functioning (hot) on a pertechnetate scan but non-functioning (cold) on a radioiodine scan. It happens because pertechnetate measures only trapping, while iodine measures trapping plus organification. Because a minority of such nodules are malignant, a pertechnetate-hot nodule in a patient being worked up for cancer risk is often confirmed with radioiodine.

Is thyroid scintigraphy regulated by the NRC?

Yes. Tc-99m and I-123 are byproduct (radioactive) material, so their medical use is governed by NRC 10 CFR Part 35 or the equivalent Agreement State program, including authorized-user requirements, dose calibrator quality control, and record-keeping. X-ray imaging, by contrast, is regulated by the FDA and state programs.

Key Takeaways

• Two tracers, two mechanisms. Pertechnetate is trapped only; iodide is trapped and organified. That difference drives timing, interpretation, and dose.
• Energy sets the collimator. 140 keV (Tc-99m) is ideal for LEHR; 159 keV (I-123) is near the limit and carries minor high-energy photons that can penetrate septa.
• Timing follows biochemistry. Image pertechnetate early (15-30 min); image iodine later (3-4 h) and quantify uptake at 24 h.
• Dose differs by retention. Pertechnetate effective dose is about 0.013 mSv/MBq; I-123 delivers more to the thyroid because it is retained.
• Discordance is a physics clue. A pertechnetate-hot, iodine-cold nodule reflects trapping without organification and can harbor malignancy.
• It is byproduct material. Thyroid scintigraphy is an NRC/Agreement State 10 CFR Part 35 activity with dose-calibrator and record requirements.

Conclusion

Thyroid scintigraphy looks simple — a small gland, a planar image, a percentage — but its reliability rests on physics decisions. The photon energy of the tracer dictates the collimator and the septal-penetration risk; the biochemistry of trapping versus organification dictates when to image and what the picture means; and retention dictates the dose. Pertechnetate and I-123 are complementary tools, not substitutes, and the discordant nodule is the clearest reminder that they probe different steps of the same pathway.

A program that matches the tracer to the clinical question, verifies collimator and energy-window performance, corrects uptake for decay, and screens for iodine loading will produce scans that are both diagnostic and defensible. The medical physicist's role in setting and validating that protocol is central to getting thyroid imaging right.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine programs in building thyroid imaging protocols that are physically sound and regulation-ready: camera and collimator performance testing, energy-window and uptake-quantification setup, dose calibrator quality control, and radiation safety program support, delivered through PET/CT and nuclear medicine physics, radiation safety officer consulting, and medical physics consulting.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

The right scan starts with the right tracer, and the right tracer starts with the physics.

Related Resources

• Thyroid uptake measurement
• I-131 thyroid cancer therapy
• Parathyroid scintigraphy with sestamibi SPECT/CT
• Gamma camera collimator selection
• Pinhole collimator magnification imaging
• Dose calibrator quality control
• PET/CT and nuclear medicine physics
• Radiation Safety Officer consulting

References

1. Giovanella L, Avram AM, Iakovou I, et al. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur J Nucl Med Mol Imaging. 2019;46(12):2514-2525. doi:10.1007/s00259-019-04472-8. PubMed
2. International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Ann ICRP. 2008;38(3). icrp.org
3. International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals — A Compendium of Current Information Related to Frequently Used Substances. Ann ICRP. 2015;44(2S). icrp.org
4. Curium US LLC. Sodium Iodide I-123 Capsules — Prescribing Information. (radiation dosimetry: effective dose approximately 2.2 mSv for 14.8 MBq at 35% thyroid uptake). drugs.com
5. Sundaraiya S, Dizdarevic S, Miles K, et al. Unusual initial manifestation of metastatic follicular carcinoma of the thyroid with thyrotoxicosis diagnosed by technetium Tc 99m pertechnetate scan: case report and review of literature. Endocr Pract. 2009;15(5):458-462. doi:10.4158/EP08300.CRR. PubMed
6. dell'Erba L, Gerundini P, Caputo M, Bagnasco M. Association of hyperfunctioning thyroid adenoma with thyroid cancer presenting as "trapping only" nodule at 99mTcO4- scintigraphy. J Endocrinol Invest. 2003;26(11):1124-1127. doi:10.1007/BF03345262. PubMed
7. Brian SR, Cheng DW, Goldberg PA. Unusual case of amiodarone-induced thyrotoxicosis: "illicit" use of a technetium scan to diagnose a transiently toxic thyroid nodule. Endocr Pract. 2007;13(4):413-416. doi:10.4158/EP.13.4.413. PubMed
8. International Commission on Radiological Protection. ICRP Publication 103: The 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37(2-4). icrp.org
9. Cherry SR, Sorenson JA, Phelps ME. Physics in Nuclear Medicine. 4th ed. Philadelphia, PA: Elsevier Saunders; 2012.
10. Gianoukakis AG, Karam M, Cheema A, Cooper JA. Autonomous thyroid nodules visualized by positron emission tomography with 18F-fluorodeoxyglucose: a case report and review of the literature. Thyroid. 2003;13(4):395-399. doi:10.1089/105072503321669893. PubMed
11. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov